The liver is one of the most well-known hypervascular organs and has a high VEGF level compared with other organs31, and cancer patients with liver metastasis showed poorer clinical benefit from anti-PD-1 monotherapy in non-small cell lung cancer (NSCLC), melanoma, or kidney cancer32. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.